SAINT LAURENT, QUEBEC and GREAT FALLS, VIRGINIA -- (MARKET WIRE) -- May 03, 2007 -- IntelGenx Technologies Corporation (OTCBB: IGXT)("IntelGenx") and Cary Pharmaceuticals ("Cary") today announced that the pilot clinical trial of QuitPak (INT003/05) showed positive intermediate results. The plasma profiles of Bupropion and Mecamylamine after administration to 7 of a total of 10 subjects demonstrate that the once-daily formulation meets the study objectives relative to area under the curve (AUC), maximum concentration (Cmax), and Time-to-peak (Tmax) for both components. The 24h pharmacokinetic profile confirms the suitability of the newly developed formulation for once-daily co-administration of Bupropion and Mecamylamine.The complete study results from all 10 subjects are expected to be available soon. The product is intended to address the lucrative $1 bn smoking cessation market.
